Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ENTX
Entera Bio Ltd. (ENTX) EV/Sales
As of 12 October 2026, Entera Bio Ltd. (ENTX) trades at a EV/Sales of 534×. Over the past ten years it has ranged from 0.0× (December 2019) to 822× (July 2026); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 9.6× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 353× | (8.40%) |
| FY2024 | 385× | 145.96% |
| FY2022 | 156× | 69.55% |
| FY2021 | 92.3× | 121.76% |
| FY2020 | 41.6× | 108.34% |
| FY2019 | 20.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 256× | (33.52%) |
| Dec 2024 | 385× | (32.02%) |
| Sep 2024 | 566× | 15.84% |
| Jun 2024 | 489× | 212.34% |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | 1.5× |
| PRTA Prothena Corporation plc compare | 2.8× |
| EDIT Editas Medicine, Inc. compare | 3.2× |
| CAPR Capricor Therapeutics, Inc. compare | 9.4× |
| ENTX Entera Bio Ltd. | 534× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)